CELC: Celcuity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Q3 net loss widened to $73.3M ($1.33/sh) from $43.8M; SG&A rose to $39.8M as REVTORPYK launched Sept 30.
What this filing says
Celcuity reported a third-quarter 2026 net loss of $73.3 million, or $1.33 per share, up from $43.8 million a year earlier, as it began commercializing REVTORPYK, which became available on September 30. Most of the rise in operating costs came from sales, general and administrative spending tied to the launch, so the loss is largely a result of building out the commercial business.
Key figures
- Q3 2026 net loss
- $73.3 million
- Q3 2026 net loss per share
- $1.33
- Prior year Q3 net loss
- $43.8 million
- Q3 2026 SG&A expenses
- $39.8 million
- Q3 2026 R&D expenses
- $37.5 million
- Q3 non-GAAP adjusted net loss
- $66.8 million
Positive for shareholders
- REVTORPYK is now commercially available in the U.S. for certain HR+/HER2- breast cancer patients.
- 91% of U.S. commercial and Medicare lives are in health plans that cover REVTORPYK.
- 78% of the top 36 strategic accounts have prescribed REVTORPYK.
Negative for shareholders
- The net loss per share more than doubled year over year, from $0.92 to $1.33.
- SG&A expenses rose to $39.8 million from $12.4 million, driven largely by hiring for the launch.
- R&D spending also increased, to $37.5 million from $30.4 million.
Written by Quantisnow AI from this filing. Not financial advice.
Form 8-K cover page
Key terms
- Non-GAAP adjusted net loss:
- A loss figure that excludes certain non-cash items such as stock-based compensation, which the company says better reflects cash used in operations.
- Stock-based compensation:
- Pay given to employees in the form of company shares or share options, recorded as an expense.
- Fulvestrant:
- A drug used with REVTORPYK to treat certain advanced breast cancers.
- HR+/HER2-:
- A subtype of breast cancer that is hormone receptor-positive and does not overexpress the HER2 protein.
FAQ
How large was Celcuity's net loss in the third quarter of 2026?
Celcuity reported a net loss of $73.3 million, or $1.33 per share, for the quarter ended September 30, 2026, compared with $43.8 million, or $0.92 per share, a year earlier.
What drove the increase in Celcuity's selling, general and administrative expenses?
The release attributes the $27.4 million rise mainly to employee-related expenses from hiring to support REVTORPYK's commercialization, plus about $11.1 million in commercialization costs such as consulting and infrastructure.
When did REVTORPYK become commercially available?
The release says REVTORPYK became commercially available in the United States on September 30, 2026.
Historical context for CELC
Across the 28 sessions after earlier CELC headlines, the stock closed higher 18 times and lower 10 times, with a median move of 3.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CELC | SPY |
|---|---|---|---|
| Nov 3, 2026 | Celcuity To Participate in Upcoming Investor Conferences | +4.0% | +0.3% |
| Oct 29, 2026 | Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call | -0.2% | -0.4% |
| Oct 26, 2026 | Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026 | +0.8% | +0.7% |
| Oct 23, 2026 | Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026 | -0.5% | -0.5% |
| Oct 22, 2026 | Cantor Fitzgerald initiated coverage on Celcuity with a new price target | +6.5% | -1.2% |
| Oct 5, 2026 | Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026 | +2.1% | +0.7% |
Keep researching CELC
- What is Form 8-K?The SEC "current report" a public company files to disclose material events, generally within four business days of the event.
- Form 8-K explainedWhat a Form 8-K is, when it is due, and what each key item number means, from 1.01 material agreements and 2.02 earnings to 4.02 restatements and 5.02 executive changes.
- CELC insider tradesEvery buy and sale reported by Celcuity Inc. officers, directors and large holders.
- CELC earnings historyPast Celcuity Inc. earnings releases, newest first.
- CELC financial statementsRevenue, profit, cash flow and balance sheet from Celcuity Inc.'s SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical Specialities
- Listed since
- 2017
Follow CELC and get a push notification the moment its next story breaks.